We are live on ! Find out more
CNMD icon

CONMED

275 hedge funds and large institutions have $3.59B invested in CONMED in 2023 Q3 according to their latest regulatory filings, with 54 funds opening new positions, 97 increasing their positions, 90 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

32% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 41

5% more funds holding

Funds holding: 263275 (+12)

8% more repeat investments, than reductions

Existing positions increased: 97 | Existing positions reduced: 90

0.12% more ownership

Funds ownership: 115.54%115.67% (+0.12%)

25% less capital invested

Capital invested by funds: $4.8B → $3.59B (-$1.21B)

27% less call options, than puts

Call options by funds: $21.9M | Put options by funds: $29.9M

Holders
275
Holders Change
+12
Holders Change %
+4.56%
% of All Funds
4.36%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
54
Increased
97
Reduced
90
Closed
41
Calls
$21.9M
Puts
$29.9M
Net Calls
-$7.93M
Net Calls Change
+$12M

CNMD Hedge Fund Activity: Q3 2023 in Review

275 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in CONMED (CNMD) for Q3 2023, worth a combined $3.59B — down 25% from $4.8B a quarter earlier.

Buyers outnumbered sellers: 54 funds opened new CNMD positions and 41 closed out — a net gain of 13 holders — while 97 added to existing stakes and 90 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $26.2M. The largest seller was JP Morgan Chase, cutting an estimated $53.8M.

  • 275 institutional investors held CONMED (CNMD) as of Q3 2023, up from 263 in Q2 2023.
  • Funds reported $3.59B of CONMED stock for Q3 2023, down 25% quarter-over-quarter.
  • 54 funds opened new CONMED positions in Q3 2023 and 41 closed out, a net change of +13 holders.
  • The largest CONMED buyer in Q3 2023 was Morgan Stanley, an estimated $26.2M added.
  • The largest CONMED seller in Q3 2023 was JP Morgan Chase, an estimated $53.8M sold.

Based on aggregated 13F filings for Q3 2023.